

# Nigel H Greig

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3847583/nigel-h-greig-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

247  
papers

15,336  
citations

68  
h-index

115  
g-index

268  
ext. papers

17,616  
ext. citations

5.7  
avg, IF

6.49  
L-index

#	Paper	IF	Citations
247	Mitophagy inhibits amyloid- $\beta$ and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. <i>Nature Neuroscience</i> , <b>2019</b> , 22, 401-412	25.5	546
246	Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 17213-8	11.5	519
245	GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 1285-90	11.5	414
244	An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 45518-28	5.4	395
243	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1664-1675	4.0	352
242	Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms. <i>Trends in Neurosciences</i> , <b>2017</b> , 40, 151-166	13.3	330
241	A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. <i>Journal of Neurochemistry</i> , <b>2001</b> , 77, 220-8	6	297
240	Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 302, 881-8	4.7	277
239	Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (A $\beta$ ) levels and protects hippocampal neurons from death induced by A $\beta$ and iron. <i>Journal of Neuroscience Research</i> , <b>2003</b> , 72, 603-12	4.4	269
238	Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. <i>International Psychogeriatrics</i> , <b>2002</b> , 14 Suppl 1, 77-91	3.4	259
237	Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. <i>Endocrinology</i> , <b>2000</b> , 141, 1936-41	4.8	248
236	Cholinesterases: roles in the brain during health and disease. <i>Current Alzheimer Research</i> , <b>2005</b> , 2, 307-18		246
235	Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function. <i>Cell Metabolism</i> , <b>2016</b> , 24, 332-40	24.6	243
234	A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 300, 958-66	4.7	234
233	GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 19, 1205-19	4.3	233
232	TNF- $\alpha$ protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. <i>Journal of Neuroinflammation</i> , <b>2012</b> , 9, 23	10.1	197
231	Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2015</b> , 12, 32-46	3	192

230	N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. <i>Current Alzheimer Research</i> , <b>2012</b> , 9, 746-58	3	191
229	Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 1855-61	8.3	182
228	Drug discovery and development: Role of basic biological research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 651-657	6	178
227	p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. <i>Annals of Neurology</i> , <b>2002</b> , 52, 597-606	9.4	178
226	Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. <i>Medicinal Research Reviews</i> , <b>1995</b> , 15, 3-31	14.4	171
225	A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. <i>Current Drug Targets</i> , <b>2003</b> , 4, 97-112	3	170
224	Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. <i>British Journal of Pharmacology</i> , <b>2012</b> , 166, 1586-99	8.6	155
223	TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. <i>Current Alzheimer Research</i> , <b>2007</b> , 4, 378-85	3	152
222	Targeting TNF- $\alpha$ to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2011</b> , 10, 391-403	2.6	150
221	Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. <i>Experimental Neurology</i> , <b>2007</b> , 203, 293-301	5.7	147
220	Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , <b>2002</b> , 1, 1-31	4.6	147
219	Current drug targets for Alzheimer's disease treatment. <i>Drug Development Research</i> , <b>2002</b> , 56, 267-281	5.1	146
218	Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. <i>Journal of Neurochemistry</i> , <b>2010</b> , 112, 1316-26	6	141
217	Tumor necrosis factor- $\beta$ synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2012</b> , 9, 106	10.1	140
216	Neuroinflammation in animal models of traumatic brain injury. <i>Journal of Neuroscience Methods</i> , <b>2016</b> , 272, 38-49	3	140
215	Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2014</b> , 13, 1432-9	2.6	137
214	Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. <i>Diabetes</i> , <b>2009</b> , 58, 318-28	0.9	135
213	Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid- $\beta$ peptide in mice. <i>Behavioural Brain Research</i> , <b>2011</b> , 225, 222-9	3.4	110

212	Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. <i>Journal of Neurochemistry</i> , <b>2007</b> , 100, 1421-9	6	108
211	Optimizing drug delivery to brain tumors. <i>Cancer Treatment Reviews</i> , <b>1987</b> , 14, 1-28	14.4	108
210	TNF- $\alpha$ induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2013</b> , 33, 1564-73	7.3	105
209	GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. <i>Pharmacology Biochemistry and Behavior</i> , <b>1991</b> , 40, 387-97	3.9	105
208	The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 320, 386-96	4.7	103
207	An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2005</b> , 2, 281-90	3	99
206	Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 15, 303-25	4.3	97
205	Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 5090-7	8.3	95
204	Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. <i>JAMA Neurology</i> , <b>2019</b> , 76, 420-429	17.2	95
203	Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2005</b> , 2, 377-85	3	93
202	Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2003</b> , 26, 2835-41	14.6	92
201	The glucagon-like peptides: a double-edged therapeutic sword?. <i>Trends in Pharmacological Sciences</i> , <b>2003</b> , 24, 377-83	13.2	90
200	A new Alzheimer's disease interventive strategy: GLP-1. <i>Current Drug Targets</i> , <b>2004</b> , 5, 565-71	3	90
199	Acetylcholinesterase and its inhibition in Alzheimer disease. <i>Clinical Neuropharmacology</i> , <b>2004</b> , 27, 141-9	1.4	89
198	Transiently lowering tumor necrosis factor- $\alpha$ synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. <i>Journal of Neuroinflammation</i> , <b>2015</b> , 12, 45	10.1	87
197	Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. <i>Journal of Neurochemistry</i> , <b>2010</b> , 113, 1621-31	6	85
196	The KATP channel activator diazoxide ameliorates amyloid- $\beta$ and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 22, 443-57	4.3	84
195	Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1990</b> , 26, 263-8	3.5	84

194	Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e32008	3.7	83
193	A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2012</b> , 11, 395-409	2.6	82
192	Tumor necrosis factor- $\beta$ synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. <i>Journal of Neurochemistry</i> , <b>2011</b> , 118, 1032-42	6	81
191	Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2014</b> , 13, 1280-93	2.6	81
190	Apoptotic and behavioral sequelae of mild brain trauma in mice. <i>Journal of Neuroscience Research</i> , <b>2007</b> , 85, 805-15	4.4	80
189	Critical role of TNF- $\beta$ in cerebral aneurysm formation and progression to rupture. <i>Journal of Neuroinflammation</i> , <b>2014</b> , 11, 77	10.1	78
188	miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 48, 563-80	4.3	78
187	New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. <i>Annals of the New York Academy of Sciences</i> , <b>2004</b> , 1035, 290-315	6.5	76
186	Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. <i>Journal of Medicinal Chemistry</i> , <b>2001</b> , 44, 4062-71	8.3	74
185	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 12506-11	11.5	72
184	Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. <i>Experimental Neurology</i> , <b>2013</b> , 239, 170-82	5.7	70
183	Early intervention with a small molecule inhibitor for tumor necrosis factor- $\beta$ prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2012</b> , 9, 99	10.1	70
182	Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 5222-9	8.3	70
181	The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2002</b> , 4, 487-96	4.3	70
180	Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. <i>Neurobiology of Disease</i> , <b>2013</b> , 54, 1-11	7.5	69
179	Exendin-4 decreases amphetamine-induced locomotor activity. <i>Physiology and Behavior</i> , <b>2012</b> , 106, 574-85	8.5	66
178	A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. <i>Cell Transplantation</i> , <b>2017</b> , 26, 1560-1571	4	66
177	Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. <i>Age</i> , <b>2013</b> , 35, 1621-36		65

176	Extension of lifespan in <i>C. elegans</i> by naphthoquinones that act through stress hormesis mechanisms. <i>PLoS ONE</i> , <b>2011</b> , 6, e21922	3.7	64
175	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. <i>Journal of Medicinal Chemistry</i> , <b>2006</b> , 49, 2174-85	8.3	64
174	Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 1919-29	8.3	62
173	Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. <i>International Journal of Molecular Sciences</i> , <b>2009</b> , 10, 1226-60	6.3	61
172	p53 is present in synapses where it mediates mitochondrial dysfunction and synaptic degeneration in response to DNA damage, and oxidative and excitotoxic insults. <i>NeuroMolecular Medicine</i> , <b>2003</b> , 3, 159-72	4.6	61
171	The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials. <i>Genes</i> , <b>2018</b> , 9,	4.2	58
170	Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. <i>Journal of Neurochemistry</i> , <b>2015</b> , 135, 1203-1217	6	58
169	Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, S62-75	1.2	58
168	Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT- $\mu$ . <i>PLoS ONE</i> , <b>2013</b> , 8, e79837	3.7	58
167	Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2010</b> , 334, 682-92	4.7	55
166	Lessons from a BACE1 inhibitor trial: off-site but not off base. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, S411-2	2.2	54
165	A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. <i>Current Alzheimer Research</i> , <b>2006</b> , 3, 81-90	3	54
164	Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. <i>Life Sciences</i> , <b>1994</b> , 55, 2037-49	6.8	53
163	Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. <i>Current Drug Targets</i> , <b>2004</b> , 5, 517-28	3	53
162	3,6'-Dithiothalidomide, a new TNF- $\alpha$ synthesis inhibitor, attenuates the effect of A $\beta$ -42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. <i>Journal of Neurochemistry</i> , <b>2012</b> , 122, 1181-92	6	52
161	Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. <i>Neurochemical Research</i> , <b>2008</b> , 33, 745-53	4.6	51
160	Insulin resistance and exendin-4 treatment for multiple system atrophy. <i>Brain</i> , <b>2017</b> , 140, 1420-1436	11.2	50
159	Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norpheneserine, their antipodal isomers, and other N(8)-substituted analogues. <i>Journal of Medicinal Chemistry</i> , <b>1997</b> , 40, 2895-901	8.3	50



158	Targets for AD treatment: conflicting messages from $\beta$ -secretase inhibitors. <i>Journal of Neurochemistry</i> , <b>2011</b> , 117, 359-74	6	49
157	Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid- $\beta$ peptide and $\beta$ levels: target engagement, tolerability and pharmacokinetics in humans. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 894-902	5.5	49
156	The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. <i>Regulatory Peptides</i> , <b>2003</b> , 114, 153-8		49
155	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. <i>Frontiers in Cell and Developmental Biology</i> , <b>2019</b> , 7, 313	5.7	49
154	Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. <i>PLoS ONE</i> , <b>2013</b> , 8, e82016	3.7	48
153	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 12703-8	11.5	47
152	The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. <i>Journal of Neural Transmission</i> , <b>2011</b> , 118, 493-507	4.3	47
151	Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 986-94	8.3	47
150	Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. <i>Biochemical Pharmacology</i> , <b>2000</b> , 60, 561-70	6	47
149	miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease. <i>Medicinal Chemistry</i> , <b>2016</b> , 12, 217-25	1.8	47
148	Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e54887	3.7	46
147	Tight binding dopamine reuptake inhibitors as cocaine antagonists. A strategy for drug development. <i>FEBS Letters</i> , <b>1989</b> , 257, 341-4	3.8	46
146	Phenserine efficacy in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 22, 1201-8	4.3	45
145	Rivastigmine lowers A $\beta$ and increases sAPP $\beta$ levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. <i>PLoS ONE</i> , <b>2011</b> , 6, e21954	3.7	45
144	Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. <i>Current Alzheimer Research</i> , <b>2008</b> , 5, 346-57	3	44
143	A new roadmap for drug development for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , <b>2014</b> , 13, 156	64.1	43
142	Neuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegeneration. <i>PLoS ONE</i> , <b>2014</b> , 9, e104973	3.7	43
141	Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 289-98	1.9	43

140	Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. <i>Experimental Neurology</i> , <b>2004</b> , 190, 133-44	5.7	43
139	Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. <i>NeuroReport</i> , <b>1995</b> , 6, 481-4	1.7	43
138	Neuroprotective effects of pifithrin- $\alpha$ against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis. <i>Scientific Reports</i> , <b>2018</b> , 8, 2368	4.9	41
137	Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. <i>FASEB Journal</i> , <b>2004</b> , 18, 1288-90	0.9	41
136	Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. <i>Journal of Neural Transmission</i> , <b>2008</b> , 115, 889-98	4.3	40
135	Lost in translation: neuropsychiatric drug development. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 61rv6	17.5	39
134	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 4360-4373	3.3	39
133	Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 34-48	1.2	38
132	A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. <i>Journal of Neuroscience Methods</i> , <b>2009</b> , 183, 182-7	3	37
131	Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. <i>Annals of the New York Academy of Sciences</i> , <b>1996</b> , 786, 348-61	6.5	37
130	Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid- $\beta$ ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. <i>Current Alzheimer Research</i> , <b>2014</b> , 11, 608-22	3	37
129	Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 318, 855-62	4.7	36
128	Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective. <i>Current Alzheimer Research</i> , <b>2017</b> , 14, 1164-1181	3	36
127	Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. <i>Experimental Neurology</i> , <b>2015</b> , 273, 151-60	5.7	35
126	Roles of p75(NTR), long-term depression, and cholinergic transmission in anxiety and acute stress coping. <i>Biological Psychiatry</i> , <b>2012</b> , 71, 75-83	7.9	35
125	Neuroprotective Mechanisms Mediated by CDK5 Inhibition. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 527-34	3.3	35
124	A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 77	5.3	34
123	Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. <i>Current Alzheimer Research</i> , <b>2005</b> , 2, 483-92	3	34



122	3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation. <i>Journal of Neuroscience Research</i> , <b>2013</b> , 91, 671-80	4.4	33
121	Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease. <i>Journal of Chromatography A</i> , <b>2009</b> , 1216, 2730-8	4.5	32
120	Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. <i>Biochemical and Biophysical Research Communications</i> , <b>1998</b> , 248, 180-5	3.4	32
119	Physovenines: Efficient Synthesis of (–) and (+)-Physovenine and Synthesis of Carbamate Analogues of (–)Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines. <i>Helvetica Chimica Acta</i> , <b>1991</b> , 74, 761-766	2	32
118	Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156493	3.7	31
117	Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins. <i>FASEB Journal</i> , <b>2020</b> , 34, 3359-3366	0.9	31
116	Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. <i>Journal of Alzheimer's Disease</i> , <b>2006</b> , 10, 43-51	4.3	30
115	Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid- $\beta$ levels. <i>PLoS ONE</i> , <b>2013</b> , 8, e58752	3.7	30
114	A Pilot Study of Exenatide Actions in Alzheimer's Disease. <i>Current Alzheimer Research</i> , <b>2019</b> , 16, 741-752	3	30
113	Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. <i>Scientific Reports</i> , <b>2017</b> , 7, 3735	4.9	29
112	The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. <i>Parkinson's Disease</i> , <b>2012</b> , 2012, 142372	3.6	29
111	In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. <i>Oncotarget</i> , <b>2016</b> , 7, 33237-45	3.3	29
110	Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 168	10.1	28
109	Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model. <i>Journal of Neurochemistry</i> , <b>2016</b> , 138, 746-57	6	28
108	Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , <b>2017</b> , 288, 176-186	5.7	27
107	Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. <i>Scientific Reports</i> , <b>2018</b> , 8, 10722	4.9	27
106	Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. <i>Acta Neurobiologiae Experimentalis</i> , <b>2004</b> , 64, 1-9	1	27
105	(-)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury. <i>Brain Research</i> , <b>2017</b> , 1677, 118-128	3.7	26

104	Post-traumatic administration of the p53 inactivator pifithrin- $\alpha$ oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury. <i>Neurobiology of Disease</i> , <b>2016</b> , 96, 216-226	7.5	26
103	Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 1818-1830	7	26
102	Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. <i>Biochemical Journal</i> , <b>2009</b> , 417, 213-22	3.8	26
101	Syntheses and anticholinesterase activities of (3aS)-N1, N8-bisnorpheneserine, (3aS)-N1,N8-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of pheneserine. <i>Journal of Medicinal Chemistry</i> , <b>1998</b> , 41, 2371-9	8.3	26
100	Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. <i>Current Alzheimer Research</i> , <b>2017</b> , 14, 1190-1197	3	26
99	Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats. <i>Journal of Neurotrauma</i> , <b>2016</b> , 33, 2044-2054	5.4	26
98	Rivastigmine modifies the $\beta$ -secretase pathway and potentially early Alzheimer's disease. <i>Translational Psychiatry</i> , <b>2020</b> , 10, 47	8.6	25
97	Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , <b>2019</b> , 36, 975-987	5.4	25
96	Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2012</b> , 11, 482-9	2.6	25
95	Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. <i>Endocrinology</i> , <b>2001</b> , 142, 4462-8	4.8	25
94	Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 431-443	1.2	25
93	Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 26, 143-55	4.3	24
92	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. <i>Bioorganic and Medicinal Chemistry</i> , <b>2010</b> , 18, 4687-93	3.4	24
91	Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 50-7	1.2	23
90	Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>2006</b> , 1760, 200-6	4	23
89	New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors. <i>Recent Patents on CNS Drug Discovery</i> , <b>2013</b> , 8, 123-41		23
88	(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice. <i>Neurobiology of Disease</i> , <b>2019</b> , 130, 104528	7.5	22
87	Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. <i>Journal of Biomedical Science</i> , <b>2017</b> , 24, 71	13.3	21

86	Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF- $\alpha$ and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of Inflammation. <i>The Open Biochemistry Journal</i> , <b>2011</b> , 5, 37-44	0.9	21
85	Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF- $\alpha$ inhibitory activity. <i>Bioorganic and Medicinal Chemistry</i> , <b>2011</b> , 19, 3965-72	3.4	21
84	Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2004</b> , 25, 581-7	5.6	21
83	Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. <i>Biochemical Journal</i> , <b>2012</b> , 444, 269-77	3.8	20
82	Adiponectin as a Potential Therapeutic Target for Prostate Cancer. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 4170-4179	3.3	20
81	The p53 inactivators pifithrin- $\alpha$ and pifithrin- $\beta$ mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagy. <i>Experimental Neurology</i> , <b>2020</b> , 324, 113135	5.7	20
80	Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, $\beta$ synuclein synthesis, interleukin-1 $\beta$ release, and cholinergic action. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , <b>2013</b> , 12, 117-28	2	19
79	Neuroinflammation and ER-stress are key mechanisms of acute bilirubin toxicity and hearing loss in a mouse model. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201022	3.7	18
78	Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. <i>Experimental Neurology</i> , <b>2017</b> , 288, 104-113	5.7	18
77	Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development. <i>Journal of Neuroscience Methods</i> , <b>2016</b> , 272, 4-18	3	17
76	Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides. <i>Journal of Organic Chemistry</i> , <b>2005</b> , 70, 6171-6	4.2	17
75	Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6'-Dithiothalidomide on Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
74	Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. <i>Future Medicinal Chemistry</i> , <b>2019</b> , 11, 489-493	4.1	16
73	Evidence of a novel mechanism for partial $\beta$ secretase inhibition induced paradoxical increase in secreted amyloid $\beta$ protein. <i>PLoS ONE</i> , <b>2014</b> , 9, e91531	3.7	16
72	Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2014</b> , 13, 338-46	2.6	16
71	Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. <i>Neurobiology of Disease</i> , <b>2019</b> , 124, 439-453	7.5	16
70	Pomalidomide Ameliorates HD $\beta$ Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	16
69	Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. <i>ACS Pharmacology and Translational Science</i> , <b>2019</b> , 2, 66-91	5.9	15

68	Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 595-602	5.9	15
67	Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development. <i>Journal of Neuroscience Methods</i> , <b>2016</b> , 272, 69-76	3	15
66	Total Synthesis of Racemic and Optically Active Compounds Related to Physostigmine and Ring-C Heteroanalogues from 3-[2?-(dimethylamino)ethyl]2,3-dihydro-5-methoxy-1,3-dimethyl-1H-indol-2-ol. <i>Helvetica Chimica Acta</i> , <b>1994</b> , 77, 1412-1422	2	15
65	Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 536257	5	15
64	Transgenerational latent early-life associated regulation unites environment and genetics across generations. <i>Epigenomics</i> , <b>2016</b> , 8, 373-87	4.4	14
63	(-)-Phenserine attenuates soman-induced neuropathology. <i>PLoS ONE</i> , <b>2014</b> , 9, e99818	3.7	14
62	In vivo biological activity of exendin (1-30). <i>Endocrine</i> , <b>2005</b> , 27, 1-9		14
61	Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. <i>Frontiers in Cell and Developmental Biology</i> , <b>2019</b> , 7, 356	5.7	14
60	Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2017</b> , 16, 820-827	2.6	13
59	3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation. <i>ELife</i> , <b>2020</b> , 9,	8.9	13
58	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , <b>2007</b> , 9, 157-68	4.6	12
57	Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis. <i>Trends in Neurosciences</i> , <b>2019</b> , 42, 151-163	13.3	12
56	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. <i>Lancet Psychiatry</i> , <b>2015</b> , 2, 756-764	23.3	11
55	Was phenserine a failure or were investigators misled by methods?. <i>Current Alzheimer Research</i> , <b>2012</b> , 9, 1174-81	3	11
54	Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 321, 353-61	4.7	11
53	A new regulatory road-map for Alzheimer's disease drug development. <i>Current Alzheimer Research</i> , <b>2014</b> , 11, 215-20	3	11
52	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , <b>2018</b> , 15, 883-891	3	11
51	Time-dependent cytokine and chemokine changes in mouse cerebral cortex following a mild traumatic brain injury. <i>ELife</i> , <b>2020</b> , 9,	8.9	11

50	Acetylcholinesterase inhibition ameliorates deficits in motivational drive. <i>Behavioral and Brain Functions</i> , <b>2012</b> , 8, 15	4.1	10
49	Neurine, an acetylcholine autolysis product, elevates secreted amyloid-beta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , <b>2006</b> , 10, 9-16	4.3	10
48	Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity. <i>Neurotoxicity Research</i> , <b>2017</b> , 32, 218-230	4.3	9
47	Pomalidomide Reduces Ischemic Brain Injury in Rodents. <i>Cell Transplantation</i> , <b>2019</b> , 28, 439-450	4	9
46	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimides for nitrite, TNF- $\alpha$ and angiogenesis inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , <b>2018</b> , 26, 1547-1559	3.4	9
45	PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 785	5.1	9
44	Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon. <i>Scientific Reports</i> , <b>2019</b> , 9, 17208	4.9	9
43	Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	9
42	Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons. <i>Neurotoxicity Research</i> , <b>2019</b> , 36, 347-356	4.3	8
41	(-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice. <i>Cell Transplantation</i> , <b>2019</b> , 28, 1183-1196	4	7
40	Neuroprotection by the Immunomodulatory Drug Pomalidomide in the LRRK2 Genetic Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 31	5.3	7
39	(-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. <i>CNS Neuroscience and Therapeutics</i> , <b>2020</b> , 26, 636-649	6.8	7
38	Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease. <i>Cells</i> , <b>2021</b> , 10,	7.9	7
37	Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid- $\beta$ Pathology in Female Rhesus Macaques ( <i>Macaca Mulatta</i> ). <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 68, 115-126	4.3	6
36	Resurrecting clinical pharmacology as a context for Alzheimer disease drug development. <i>Current Alzheimer Research</i> , <b>2009</b> , 6, 79-81	3	6
35	Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF- $\alpha$ p38 kinase and JNK kinase. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , <b>2013</b> , 12, 129-35	2	6
34	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 656921	5.1	6
33	Role of viruses, prions and miRNA in neurodegenerative disorders and dementia. <i>VirusDisease</i> , <b>2018</b> , 29, 419-433	3.4	6



32	Post-treatment with Posiphen Reduces Endoplasmic Reticulum Stress and Neurodegeneration in Stroke Brain. <i>IScience</i> , <b>2020</b> , 23, 100866	6.1	5
31	Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, E4820	11.5	5
30	Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , <b>2020</b> , 324, 113113	5.7	5
29	High Throughput Virtual Screening and Molecular Dynamics Simulation for Identifying a Putative Inhibitor of Bacterial CTX-M-15. <i>Antibiotics</i> , <b>2021</b> , 10,	4.9	5
28	Is insulin resistance the cause of fibromyalgia? A preliminary report. <i>PLoS ONE</i> , <b>2019</b> , 14, e0216079	3.7	4
27	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. <i>Molecules</i> , <b>2020</b> , 25,	4.8	4
26	Sequential combined Treatment of Pifithrin- $\alpha$ and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke. <i>Cell Transplantation</i> , <b>2018</b> , 27, 607-621	4	4
25	Amyloid- $\beta$ precursor protein synthesis inhibitors for Alzheimer's disease treatment. <i>Annals of Neurology</i> , <b>2014</b> , 76, 629-30	9.4	4
24	Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 20353	5.4	4
23	Age-related impairment of cerebral blood flow response to K channel opener in Alzheimer's disease mice with presenilin-1 mutation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2021</b> , 41, 1579-1591	7.3	4
22	-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. <i>ACS Pharmacology and Translational Science</i> , <b>2021</b> , 4, 980-1000	5.9	4
21	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. <i>ACS Pharmacology and Translational Science</i> , <b>2021</b> , 4, 858-869	5.9	4
20	3,6'-Dithiopomalidomide Ameliorates Hippocampal Neurodegeneration, Microgliosis and Astrogliosis and Improves Cognitive Behaviors in Rats with a Moderate Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
19	Can We Prevent Dementia and Not Prevent Neurons from Dying?. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 68, 489-492	4.3	2
18	Diphtheria toxin induced but not CSF1R inhibitor mediated microglia ablation model leads to the loss of CSF/ventricular spaces in vivo that is independent of cytokine upregulation.. <i>Journal of Neuroinflammation</i> , <b>2022</b> , 19, 3	10.1	1
17	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease <b>2007</b> , 9, 157		1
16	Thionation of Aminophthalimide Hindered Carbonyl Groups and Application to the Synthesis of 3,6'-Dithionated Pomalidomides. <i>Synlett</i> , <b>2021</b> , 32, 917-922	2.2	1
15	nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse. <i>Scientific Reports</i> , <b>2021</b> , 11, 9711	4.9	1



14	Geriatric pharmacotherapy: Appraising new drugs for neurologic disorders in older patients. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 3-18</i>	3	1
13	Dissociation Between the Potent $\beta$ Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine <b>2008, 445-462</b>		1
12	Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.. <i>Alzheimerjs and Dementia, 2022,</i>	1.2	1
11	Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.. <i>Neurotherapeutics, 2022, 1</i>	6.4	0
10	and Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes.. <i>ACS Pharmacology and Translational Science, 2022, 5, 70-79</i>	5.9	0
9	Exploring N(1)-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment. <i>CNS and Neurological Disorders - Drug Targets, 2014, 13, 197-202</i>	2.6	0
8	The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. <i>Journal of Neurochemistry, 2021, 159, 867-886</i>	6	0
7	3,6?- and 1,6?-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. <i>Pharmaceutics, 2022, 14, 950</i>	6.4	0
6	Neuronal Hyperexcitability Following mTBI <b>2019, 67-81</b>		
5	GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR6-4</i>		0
4	Inhibition of butyrylcholinesterase improves prepulse inhibition deficits and enhances M1 muscarinic acetylcholine receptor-mediated responses via ghrelin signaling in mice. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-134</i>		0
3	Posiphen $\beta$ new experimental drug to understand and mitigate age-related neurodegenerative disorders. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY54-3</i>		0
2	P3-061: CONSTITUTIVE IN VIVO OVEREXPRESSION OF MIR146A AND MIR200B INDEPENDENTLY MODULATES LEVELS OF ALZHEIMER'S DISEASE (AD)- RELATED PROTEINS IN THE MOUSE HIPPOCAMPUS AND CEREBRAL CORTEX <b>2018, 14, P1088-P1088</b>		
1	P3-053: (-)-PHENSERINE (PHEN) AND THE PREVENTION OF PRE-PROGRAMMED CELL DEATH IN ALZHEIMER'S DISEASE (AD) AND MILD TRAUMATIC BRAIN INJURY (MTBI) <b>2018, 14, P1083-P1083</b>		